Dendreon and Provenge (2010–2015)
Dendreon won FDA approval for Provenge, an immunotherapy for advanced prostate cancer, in 2010. Manufacturing costs and commercial struggles outpaced revenue, and the company filed for Chapter 11 in 2014.
Dendreon emerged from bankruptcy in 2015; Valeant Pharmaceuticals bought it later that year.
Provenge still sells under new owners, showing approved cell therapies can outlive their original companies.
Both stories show how cell-therapy companies end up in distress — Dendreon after approval, Longeveron after a failed trial — and get reshaped by new capital and owners.
